Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) rose 0.5% on Thursday . The company traded as high as $4.42 and last traded at $4.39. 435,521 shares were traded during mid-day trading, an increase of 67% from the average daily volume of 261,100 shares. The stock had previously closed at $4.37.
Aadi Bioscience Price Performance
The firm has a 50-day moving average of $4.27 and a 200-day moving average of $3.45. The stock has a market cap of $102.74 million, a PE ratio of -1.82 and a beta of 0.68.
Aadi Bioscience Company Profile
Aadi Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company’s research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways.
The company’s lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).
Featured Articles
- Five stocks we like better than Aadi Bioscience
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
- MarketBeat Week in Review – 06/22 – 06/26
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
